Prostate cancer genomics, biology, and risk assessment through genome-wide association studies

Cancer Science

Volumn 103, Issue 4, 2012, Pages 607-613

  Nakagawa, Hidewaki ^a   Akamatsu, Shusuke ^a,b   Takata, Ryo ^a,c   Takahashi, Atsushi ^a   Kubo, Michiaki ^a   Nakamura, Yusuke ^d  

^a RIKEN   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; JAZF ZINC FINGER 1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHROMOSOME 8Q; CHROMOSOME 8Q24; FAMILIAL CANCER; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN, PAIR 8; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE;

EID: 84859005156     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02193.x     Document Type: Review

References (79)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-64.
2. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001; 23: 3-13.
3. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13: R103-21.
4. Lichtenstein P, Holm N, Verkasalo P et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2001; 343: 78-85.
5. Matsuda T, Saika K. Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 2009; 39: 468-9.
6. Shimizu H, Ross R, Bernstein L et al. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles. Br J Cancer 1991; 63: 963-6.
7. Carpten J, Nupponen N, Isaacs S et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 181-4.
8. Tavtigian SV, Simard J, Teng DH et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 172-80.
9. Xu J, Zheng SL, Komiya A et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-5.
10. Edwards SM, Kote-Jarai Z, Meitz J et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12.
11. Chang BL, Zheng SL, Isaacs SD et al. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate 2003; 56: 37-44.
12. Wang F, Zou YF, Feng XL et al. CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 2011; 71: 1167-77.
13. Chang BL, Zheng SL, Hawkins GA et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002; 62: 1784-9.
14. Ntais C, Polycarpou A, Ioannidis JP. Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2005; 14: 176-81.
15. Chen L, Davey Smith G, Evans DM et al. Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 2009; 18: 2874-81.
16. Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
17. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7.
18. Haiman CA, Patterson N, Freedman ML et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638-44.
19. Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
20. Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
21. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
22. Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
23. Yeager M, Chatterjee N, Ciampa J et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 2009; 41: 1055-7.
24. Al Olama AA, Kote-Jarai Z, Giles GG et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
25. Gudmundsson J, Sulem P, Gudbjartsson DF et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-6.
26. Eeles R, Kote-Jarai Z, Al Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-21.
27. Takata R, Akamatsu S, Kubo M et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-4.
28. Kote-Jarai Z, Al Olama AA, Giles GG et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-9.
29. Haiman CA, Chen GK, Blot WJ et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011; 43: 570-3.
30. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol 2010; 7: 394-400.
31. Konety BR, Bird VY, Deorah S et al. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005; 174: 1785-8.
32. Xu J, Zheng SL, Isaacs SD et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 2010; 107: 2136-40.
33. Tomlinson I, Webb E, Carvajal-Carmona L et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007; 39: 984-8.
34. Zanke BW, Greenwood CM, Rangrej J et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007; 39: 989-94.
35. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
36. Goode EL, Chenevix-Trench G, Song H et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42: 874-9.
37. Kiemeney LA, Thorlacius S, Sulem P et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40: 1307-12.
38. Ghoussaini M, Song H, Koessler T et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008; 100: 962-6.
39. Tuupanen S, Turunen M, Lehtonen R et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009; 41: 885-90.
40. Pomerantz MM, Ahmadiyeh N, Jia L et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009; 41: 882-4.
41. Jia L, Landan G, Pomerantz M et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet 2009; 5: e1000597.
42. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010; 20: 1191-7.
43. Ahmadiyeh N, Pomerantz MM, Grisanzio C et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci USA 2010; 107: 9742-6.
44. Pomerantz MM, Beckwith CA, Regan MM et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009; 69: 5568-74.
45. Robbins C, Torres JB, Hooker S et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007; 17: 1717-22.
46. Chung S, Nakagawa H, Uemura M et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 2011; 102: 245-52.
47. Chu LW, Meyer TE, Li Q et al. Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev 2010; 19: 1848-54.
48. Chang B, Cramer S, Wiklund F et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009; 18: 1368-75.
49. Lou H, Yeager M, Li H et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 association with prostate cancer susceptibility. Proc Natl Acad Sci USA 2009; 106: 7933-8.
50. Shukeir N, Arakelian A, Kadhim S et al. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003; 63: 2072-8.
51. Akamatsu S, Takata R, Ashikawa K et al. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 2010; 19: 4265-72.
52. Bhatia-Gaur R, Donjacour A, Sciavolino P et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999; 13: 966-77.
53. Wang X, Kruithof-de Julio M, Economides K et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461: 495-500.
54. Bova G, Carter B, Bussemakers M et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993; 53: 3869-73.
55. He W, Sciavolino P, Wing J et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43: 69-77.
56. Voeller H, Augustus M, Madike V et al. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997; 57: 4455-9.
57. Haiman CA, Chen GK, Blot WJ et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS ONE 2011; 7: e1001387.
58. Pi M, Chen L, Huang MZ et al. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS ONE 2008; 3: e3858.
59. Pi M, Quarles LD. GPRC6A regulates prostate cancer progression. Prostate 2011; DOI: 10.1002/pros.21442 [Epub ahead of print].
60. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 2004; 47: 1071-8.
61. Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.
62. Lindner TH, Njolstad PR, Horikawa Y et al. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 1999; 8: 2001-8.
63. Pontoglio M. Hepatocyte nuclear factor 1, a transcription factor at the crossroads of glucose homeostasis. J Am Soc Nephrol 2000; 11: S140-3.
64. Spurdle AB, Thompson DJ, Ahmed S et al. Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nat Genet 2011; 43: 451-4.
65. Li L, Yang Y, Yang G et al. The role of JAZF1 on lipid metabolism and related genes in vitro. Metabolism 2011; 60: 523-30.
66. Soranzo N, Rivadeneira F, Chinappen-Horsley U et al. Meta-analysis of genome-wide scans for human adult stature identifies novel loci and associations with measures of skeletal frame size. PLoS Genet 2009; 5: e1000445.
67. Zeggini E, Scott LJ, Saxena R et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638-45.
68. Frayling TM, Colhoun H, Florez JC. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008; 51: 1757-60.
69. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigne and prostate cancer: prediction, detection and monitering. Nat Rev Cancer 2008; 8: 268-78.
70. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
71. Gudmundsson J, Bessenbacher S, Sulem P et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010; 2: 62ra92.
72. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
73. Salinas CA, Koopmeiners JS, Kwon EM et al. Clinical utulity of five genetic variants for predicting prostate cancer risk and mortaliy. Prostate 2008; 69: 363-72.
74. Zheng SL, Sun J, Wiklund F et al. Genetic variants and family history predict prostsate cancer similar to prostate-specific antigen. Clin Cancer Res 2009; 15: 1105-11.
75. Nam RK, Zhang WW, Trachtenberg J et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009; 15: 1787-93.
76. Xu J, Sun J, Kader AK et al. Estimation of absolute risk for prostate cancer uisng genetic markers and family history. Prostate 2009; 69: 1565-72.
77. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-48.
78. Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutesteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202.
79. Freedman ML, Monteiro ANA, Gayther SA et al. Principles for the post-GWAS functional characterization of cancedr risk loci. Nat Genet 2011; 43: 513-8.